ICER takes on Aetion’s RWE platform

By Jenni Spinner

- Last updated on GMT

ICER takes on Aetion’s RWE platform

Related tags Real-world evidence Real-world data

The ICER plans to harness the company’s technology to expand use of real-world evidence.

As a health technology assessment (HTA) organization, ICER works to evaluate how emerging medical interventions serve to improve patients’ lives. It also suggests benchmark prices that fall in line with an intervention’s benefit to patients and the overall healthcare system.

In its 2020 Value Assessment Framework, ICER outlined plans to generate RWE for assessments. Additionally, the group recently laid the groundwork for harnessing RWE in two-year reevaluations of US FDA-approved drugs, under accelerated approval routes.

Broad health industry benefits

An Aetion spokesperson told Outsourcing-Pharma that the use of RWE benefits people across the healthcare spectrum.

It furthers ICER’s mission of catalyzing a movement toward fair pricing, fair access, and future innovation across the entire US health system​,” they said.

Pamela Bradt, chief scientific officer for ICER, said analytics from Aetion’s Evidence Platform will empower the organization to more efficiently gather evidence for its review process.

“Through this partnership, we aim to set new standards for how RWE can better inform the consequential decisions that biopharma manufacturers, insurers, and other stakeholders make every single day around drug pricing and patient access,”​ Bradt said.

Sharing information

According to Aetion, protocols developed via the partnership with ICER will be included in assessments that ICER shares publicly. The open sharing of information, in turn, will benefit other stakeholders in the industry.

Integrating RWE into ICER’s assessments will advance how we as a health care industry—and a society—determine value​,” said Carolyn Magill, CEO of Aetion.

Aetion has partnered with several organizations and companies to promote use of RWE. In August 2018, Harvard Medical School and Brigham’s Women’s Hospital​ tapped the Evidence Platform to support their Reproducible Evidence Practices to Enhance and Achieve Transparency (REPEAT) program.

Additionally, in October 2019, McKesson and Aetion​ announced a collaboration to advance the use of RWE in cancer research.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more